Liminal BioSciences (TSX:LMNL) and its collaborators will present preclinical findings on a novel therapeutic approach to the treatment of inflammatory and fibrosis-related kidney diseases at the American Society of Nephrology conference on Nov. 5-to-10 in Washington, DC.
“We believe that free fatty acid receptors, GPR40 and GPR84, are promising targets for the unmet patient needs in the treatment of inflammatory and fibrosis-related kidney diseases,” Kenneth Galbraith, CEO of Liminal, said in a statement.
“Based on our research to date, we expect to nominate a drug candidate from our compound library to pursue continued development in kidney disease before the end of 2019,” he added.
